Details.
Includes dossier evaluation and compilation, regulatory agency liaison, submissions for new chemical entities, new biological entities, generics, biosimilars, non-biological complex generic medicines and fixed dose combination products, portfolio lifecycle management, literature based submissions, orphan designations, priority review and provisional determinations, rescheduling applications, appeals, restricted representation and exemption methods.